Download PDF
Nephrologie aktuell 2024; 28(10): 464-471
DOI: 10.1055/a-2415-9576
Schwerpunkt
Nephrologie

Evidenzbasierte Therapie von Hyperphosphatämie und Vitamin-D-Mangel

Wieviel Intervention ist in Zeiten der SGLT-2-Hemmer erforderlich?
Gunnar Henrik Heine
1   Agaplesion Markus Krankenhaus, Frankfurt am Main
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

ZUSAMMENFASSUNG

Patienten mit einer chronischen Nierenkrankheit (CKD: „chronic kidney disease“) weisen eine hohe kardiovaskuläre Morbidität und Mortalität auf. Auf traditionelle Risikofaktoren der Atherosklerose zielende Strategien, die in der Allgemeinbevölkerung erfolgreich sind, erbringen jedoch bei schwerer CKD keinen eindeutigen Benefit. Daher haben Präventionsstrategien bei CKD lange auf nichttraditionelle Risikofaktoren fokussiert – insbesondere auf Komponenten der CKD-assoziierten Mineral- und Knochenstörungen (CKD-MBD: „chronic kidney disease – mineral and bone disorder“). Allerdings ist die Evidenz für eine kardiovaskuläre Risikoreduktion durch die Therapie der CKD-MBD begrenzt. Jenseits der CKD-MBD sind nun mit SGLT-2-Inhibitor (SGLT-2: „sodium-glucose linked transporter 2“), GLP-1-Analoga (GLP-1: „glucagon-like peptide-1“) und nichtsteroidalem Mineralo-Kortikoid-Rezeptor-Antagonist Pharmaka verfügbar, die in Phase-III-Studien eine klare kardiovaskuläre Risikoreduktion erlaubt haben und zudem bei nichtdialysepflichtiger CKD nephroprotektiv sind. Daher sollten nun Therapiestrategien der CKD-MBD kritisch reevaluiert werden.



Publication History

Article published online:
12 December 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Lindner A, Charra B, Sherrard DJ. et al Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 1974; 290: 697-701
    CrossrefPubMedSearch in Google Scholar
  • 2 Go AS, Chertow GM, Fan D. et al Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305
    CrossrefPubMedSearch in Google Scholar
  • 3 Van Der Velde M, Matsushita K, Coresh J. et al Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int 2011; 79: 1341-52
    CrossrefPubMedSearch in Google Scholar
  • 4 Wanner C, Krane V, März W. et al Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353: 238-248
    CrossrefPubMedSearch in Google Scholar
  • 5 Fellström BC, Jardine AG, Schmieder RE. et al Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009; 360: 1395-1407
    CrossrefPubMedSearch in Google Scholar
  • 6 Heine GH, Nangaku M, Fliser D. Calcium and phosphate impact cardiovascular risk. Eur Heart J 2013; 34: 1112-1121
    CrossrefPubMedSearch in Google Scholar
  • 7 Heine GH. Mineral metabolism in heart disease. Curr Opin Nephrol Hypertens 2015; 24: 310-316
    CrossrefPubMedSearch in Google Scholar
  • 8 Ketteler M, Bover J, Mazzaferro S. Treatment of secondary hyperparathyroidism in non-dialysis CKD: an appraisal 2022 s. Nephrol Dial Transplant 2023; 38: 1397-1404
    CrossrefPubMedSearch in Google Scholar
  • 9 Brandenburg V, Ketteler M. Vitamin D and secondary hyperparathyroidism in chronic kidney disease: a critical appraisal of the past, present, and the future. Nutrients 2022; 14: 3009
    CrossrefPubMedSearch in Google Scholar
  • 10 Jørgensen HS, de Loor H, Billen J. et al Vitamin D metabolites before and after kidney transplantation in patients who are anephric. Am J Kidney Dis 2024; 84: 427-436.e1
    CrossrefPubMedSearch in Google Scholar
  • 11 Manson JE, Cook NR, Lee I-M. et al Vitamin D supplements and prevention of cancer and cardiovascular disease. N Engl J Med 2019; 380: 33-44
    CrossrefPubMedSearch in Google Scholar
  • 12 Limonte CP, Zelnick LR, Hoofnagle AN. et al Effects of vitamin D3 supplementation on cardiovascular and cancer outcomes by eGFR in VITAL. Kidney360 2022; 3: 2095-2105
    CrossrefPubMedSearch in Google Scholar
  • 13 De Boer IH, Zelnick LR, Ruzinski J. et al Effect of vitamin D and Omega-3 fatty acid supplementation on kidney function in patients with type 2 diabetes: A randomized clinical trial. JAMA 2019; 322: 1899-1909
    CrossrefPubMedSearch in Google Scholar
  • 14 Emerging Risk Factors Collaboration/EPIC-CVD/Vitamin D Studies Collaboration. Estimating dose-response relationships for vitamin D with coronary heart disease, stroke, and all-cause mortality: observational and Mendelian randomisation analyses. Lancet Diabetes Endocrinol 2024; 12: e2-e11
    CrossrefPubMedSearch in Google Scholar
  • 15 Thadhani R, Appelbaum E, Pritchett Y. et al Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: The PRIMO randomized controlled trial. JAMA 2012; 307: 674-684
    CrossrefPubMedSearch in Google Scholar
  • 16 Wang AYM, Fang F, Chan J. et al Effect of paricalcitol on left ventricular mass and function in CKD – The OPERA trial. J Am Soc Nephrol 2014; 25: 175-186
    CrossrefPubMedSearch in Google Scholar
  • 17 J-DAVID Investigators, Shoji, T, Inaba M et al. Effect of oral alfacalcidol on clinical outcomes in patients without secondary hyperparathyroidism receiving maintenance hemodialysis: the J-DAVID randomized clinical trial. JAMA 2018; 320: 2325-2334
    CrossrefPubMedSearch in Google Scholar
  • 18 Ogata H, Fukagawa M, Hirakata H. et al Effect of treating hyperphosphatemia with lanthanum carbonate vs calcium carbonate on cardiovascular events in patients with chronic kidney disease undergoing hemodialysis: the LANDMARK randomized clinical trial. JAMA 2021; 325: 1946-1954
    CrossrefPubMedSearch in Google Scholar
  • 19 Lioufas NM, Pascoe EM, Hawley CM. et al Systematic review and meta-analyses of the effects of phosphate-lowering agents in nondialysis CKD. J Am Soc Nephrol 2022; 33: 59-76
    CrossrefPubMedSearch in Google Scholar
  • 20 Edmonston DL, Isakova T, Dember LM. et al Design and rationale of HiLo: a pragmatic, randomized trial of phosphate management for patients receiving maintenance hemodialysis. Am J Kidney Dis 2021; 77: 920-930.e1
    CrossrefPubMedSearch in Google Scholar
  • 21 EVOLVE Trial Investigators, Chertow GM, Block GA et al. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 2012; 367: 2482-2494
    CrossrefPubMedSearch in Google Scholar
  • 22 Middleton JP, Wolf M. Second chances to improve ESRD outcomes with a second-generation calcimimetic. JAMA 2017; 317: 139-141
    CrossrefPubMedSearch in Google Scholar
  • 23 Hiatt WR, Kaul S, Smith RJ. The cardiovascular safety of diabetes drugs — insights from the rosiglitazone experience. N Engl J Med 2013; 369: 1285-1287
    CrossrefPubMedSearch in Google Scholar
  • 24 Wanner C, Inzucchi SE, Lachin JM. et al Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016; 375: 323-334
    CrossrefPubMedSearch in Google Scholar
  • 25 Mann JFE, Ørsted DD, Brown-Frandsen K. et al Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med 2017; 377: 839-848
    CrossrefPubMedSearch in Google Scholar
  • 26 The EMPA-KIDNEY Collaborative Group, Herrington WG, Staplin N et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med 2023; 388: 117-127
    CrossrefPubMedSearch in Google Scholar
  • 27 Heerspink HJL, Stefánsson BV, Correa-Rotter R. et al Dapagliflozin in patients with chronic kidney disease. N Engl J Med 2020; 383: 1436-1446
    CrossrefPubMedSearch in Google Scholar
  • 28 Perkovic V, Tuttle KR, Rossing P. et al Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med 2024; 391: 109-121
    CrossrefPubMedSearch in Google Scholar
  • 29 Pitt B, Filippatos G, Agarwal R. et al Cardiovascular events with finerenone in kidney disease and type 2 diabetes. NEngl J Med 2021; 385: 2252-2263
    CrossrefPubMedSearch in Google Scholar
  • 30 Bakris GL, Agarwal R, Anker SD. et al Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med 2020; 383: 2219-2229
    CrossrefPubMedSearch in Google Scholar
  • 31 Lewis EJ, Hunsicker LG, Bain RP. et al The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456-1462
    CrossrefPubMedSearch in Google Scholar
  • 32 Parving HH, Lehnert H, Brochner-Mortensen J. et al The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878
    CrossrefPubMedSearch in Google Scholar
  • 33 Brenner BM, Cooper ME, de Zeeuw D. et al Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869
    CrossrefPubMedSearch in Google Scholar
  • 34 Neuen BL, Heerspink HJL, Vart P. et al Estimated lifetime cardiovascular, kidney, and mortality benefits of combination treatment with SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal MRA compared with conventional care in patients with type 2 diabetes and albuminuria. Circulation 2024; 149: 450-462
    CrossrefPubMedSearch in Google Scholar
  • 35 Rau M, Thiele K, Hartmann NUK. et al Effects of empagliflozin on markers of calcium and phosphate homeostasis in patients with type 2 diabetes – data from a randomized, placebo-controlled study. Bone Rep 2022; 16: 101175
    CrossrefPubMedSearch in Google Scholar
  • 36 Neuen BL, Tuttle KR, Vaduganathan M. Accelerated risk-based implementation of guideline-directed medical therapy for type 2 diabetes and chronic kidney disease. Circulation 2024; 149: 1238-1240
    CrossrefPubMedSearch in Google Scholar
  • 37 Baigent C, Landray MJ, Reith C. et al The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011; 377: 2181-2192
    CrossrefPubMedSearch in Google Scholar
  • 38 März W, Genser B, Drechsler C. et al Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis. Clin J Am Soc Nephrol 2011; 6: 1316-1325
    CrossrefPubMedSearch in Google Scholar